Bloomberg -- Bavarian Nordic A/S, which is testing a prostate cancer vaccine, rose as much as 6.5 percent in Copenhagen trading after getting U.S. approval to proceed with the last trial required of the experimental medicine.
The U.S. Food and Drug Administration has reviewed and approved the trial’s design and goals in a special protocol assessment, the Kvistgaard, Denmark-based drugmaker said today.
